Gujarat Fluoroch Q3 FY26 Earnings Analysis

Published 5 Aug 2026 | Chemicals & Petrochemicals | Market Cap: ₹49.3K Cr

Price

4,498.1

Market Cap

₹49.3K Cr

P/E Ratio

83.9

Earnings Summary

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

📊 Revenue & Sales Performance

No information is provided regarding the same in the latest conference call.

📈 Profitability & Margins

No information is provided regarding the same in the latest conference call.

🏗️ Capital Expenditure Plans

No information is provided regarding the same in the latest conference call.

💰 Fundraising & Capital Structure

No information is provided regarding the same in the latest conference call.

📋 Order Book & Pipeline

No information is provided regarding the same in the latest conference call.

Key Metrics

Frequently Asked Questions

What were Gujarat Fluoroch Q3 FY26 results?

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

What is Gujarat Fluoroch share price analysis?

Gujarat Fluoroch currently shows a neutral. The stock trades at a P/E of 83.9 with a market cap of ₹49,338. Investors should review the full earnings analysis for detailed insights.

Is Gujarat Fluoroch planning capital expenditure?

No information is provided regarding the same in the latest conference call.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

Others in Chemicals & Petrochemicals this season

  • Rajputana Bio. (Q3 FY26)

    Rajputana Bio. Q3 FY26 quarterly results analysis. - Rajputana Biodiesel aims to operate at nearly 100% capacity at its enhanced Indian units next year. Market

  • Indian Emuls (Q3 FY26)

    Indian Emuls Q3 FY26 quarterly results analysis. - For FY '26, the company expects revenue growth upward of 100%, with projections between 150% to 200% growth c

  • Tatva Chintan Pharma Chem Ltd (Q3 FY26)

    Tatva Chintan Q3 FY26 quarterly results analysis. - **SDA Segment**: Strong volume uptick expected from 2026 onward as new customers onboard; pricing bottomed o

  • Clean Science & Technology Ltd (Q3 FY26)

    Clean Science Q3 FY26 quarterly results analysis. - HALS segment expected to continue growing quarter-on-quarter, with 25% volume growth already seen in Q2 and